Eco antibiotic drives strong sales growth; Patterson declares cash dividend; UC Davis scientists report success preventing tumors in foxes;

> Eco Animal Health reported that in the 6 months ended Sept. 30, its revenues jumped 27% year-over-year to £21.5 million ($32.5 million) and its adjusted earnings before taxes, depreciation and amortization rose 26% to £4.3 million ($6.5 million), driven largely by demand for its poultry and swine antibiotic Aivlosin. Release

> Patterson Companies ($PDCO) declared a quarterly cash dividend of $0.22 per share, payable January 22. Release

> Wildlife specialists at the University of California, Davis, reported in the journal PLOS ONE that by administering a commonly used treatment for ear mites in dogs and cats called acaracide to wild foxes on Catalina Island, they reduced ear mite infection rates from 98% to 10%, greatly decreasing inflammation of the animals' ear canals, which can lead to tumors when untreated. Release

> Bravo Pet Foods announced it is recalling a lot of Bravo Chicken Blend diet for dogs and cats and three additional products manufactured the same day due to possible contamination with Salmonella. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…